Browse more cannabis research, findings, methods, and limitations.
Machine learning found medical cannabis shifted salivary biomarkers in autistic children toward typical levels, with THC and CBD producing distinct metabolic signatures.
15-year Swedish study of 12,143 CUD patients found 23% readmission rate, with schizophrenia (54% higher), low education (40% higher), and ages 18-35 as top risk factors.
A Swedish registry study of 3.3 million people found CUD diagnoses rising in younger cohorts, with 80% psychiatric comorbidity and distinct gender-linked subgroups.
First case report of cannabis-assisted psychotherapy for dissociative PTSD showed dramatic improvement over 10 sessions, drawing parallels to psychedelic-assisted therapy.
A retrospective review of 141 MS patients found 72% reported pain relief with medical cannabis, and opioid use dropped significantly.
Recreational cannabis laws in 11 US states were associated with reduced codeine dispensing at pharmacies, while other opioid types were unaffected.
Low-dose oral cannabis reversed insulin resistance in diabetic rats, with different fat depots responding through distinct mechanisms.
Among 205 people using opioids in Vancouver, 58% used cannabis to manage cravings, and this was linked to self-reported reductions in opioid use.
Review of CBD (Epidiolex) clinical evidence shows efficacy for seizures in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, with unresolved dosing and interaction challenges.
Review argues epigenomic evidence links cannabis exposure to birth defects, cancer, and accelerated aging through DNA methylation disruption across generations.
US ecological study found daily cannabis use and first-trimester exposure were statistically associated with autism rates in 40 million children, with exponential dose-response patterns.
Lab study showed CBD oil and vitamin E acetate in vaping aerosols accumulated on and inside human airway cells, causing dramatic cell death and metabolic stress.
Scoping review of 2,589 articles found only 22 studying cannabis in ICU settings, revealing major research gaps and inconsistent findings on outcomes.
Among 167,095 ICU pneumonia patients, alcohol misuse increased mortality while cannabis misuse showed no independent association after statistical adjustment.
Computational screening and lab testing found CBD selectively inhibits brain enzyme PDE9 at nanomolar concentrations, suggesting a potential neuroprotective mechanism.
Mini-review of 12 studies found suggestive evidence that cannabis use increases suicide risk in schizophrenia, particularly among men and during first-episode psychosis.
Among 62 first-episode psychosis patients, synthetic cannabinoid users showed worse symptoms, slower recovery, and higher aberrant salience than THC users or non-users.
Among 61 first-episode psychosis patients followed for 9 months, synthetic cannabinoid users had worse symptoms, more suicidal ideation, and poorer recovery than THC users or non-users.
Placebo-controlled crossover trial found THC/CBD cannabis oil helped 60% of insomnia patients no longer qualify as clinical insomniacs, with increased melatonin and sleep duration.
Oklahoma ED visits for cannabinoid hyperemesis syndrome increased significantly after medical cannabis legalization, with prevalence far higher than previously reported.
In female rats, high-CBD cannabis vapor reduced opioid reward and fentanyl self-administration with no abuse potential and a robust safety profile.
CBD injected into the amygdala reversed pain sensitivity caused by living with a partner in chronic pain, working through serotonin 5-HT3 receptors.
Review found cannabis may help brain tumor patients with nausea, pain, appetite, and seizures, but standardized dosing guidance and clinical trials are lacking.
Systematic review of 13 animal studies found CB2 cannabinoid receptors in brain reward areas are necessary for modulating food intake and energy balance.
CDC data showed cannabis ED visits among youth increased during the COVID pandemic, with the steepest rises in children under 10 and a notable shift to higher rates among adolescent girls.
Registry data from all three Scandinavian countries showed cannabis-induced psychosis doubled while alcohol-induced psychosis declined from 2000 to 2016.
Review found cannabinoid receptors throughout the placenta and evidence that THC and CBD exposure can disrupt placental development, contributing to fetal growth restriction.
Among 352 Colombian adolescents, cannabis and tranquilizer use were independently linked to suicidal behavior alongside depression, aggression, and borderline traits.
Cross-species analysis found only 5 of 14 endocannabinoid receptors had matching expression across mice, rats, and monkeys, revealing a translational research challenge.
Study revealed CBD prevents seizures by blocking a lipid (LPI) that simultaneously boosts excitatory and weakens inhibitory signaling in the hippocampus through GPR55 receptors.
Review found adolescent cannabis use disrupts critical brain development, with concern that new high-potency products and delivery devices amplify the risk.
Pilot RCT of 17 volunteers found 600mg CBD did not alter ayahuasca's effects on social cognition, with good tolerability and no safety concerns.
After legalization, 4.7% of Canadian cannabis users showed impaired control, with higher risk among young males, early initiators, and those with mental health conditions.
Review highlighted that combined alcohol-cannabis use during pregnancy is increasingly common but virtually unstudied, despite evidence that co-use amplifies effects.
National survey found 6.3% of US drivers aged 16-20 reported driving after cannabis use, more than double the alcohol DUI rate of 2.6%.
CBD extended sleep in rats but disrupted sleep oscillations critical for memory, impairing complex memory consolidation while leaving simple memory intact.
Review for gastroenterologists found cannabis has potential GI benefits through the endocannabinoid system but risks include hyperemesis, dependency, and cognitive effects.
Nationwide data showed heart attacks among young cannabis users nearly tripled from 2007 to 2018, with the steepest increase among Black Americans.
Prenatal cannabis smoke exposure in rats altered litter sex ratio, increased adult offspring anxiety, changed amygdala genes, but improved some cognitive tasks.
Adolescent THC edible experience in rats enhanced alcohol's stimulant effects and altered frontal cortex endocannabinoid levels during alcohol withdrawal.
Clinical review found FAAH enzyme modulates mood, pain, reward, and appetite, but drug trials targeting it have underperformed relative to animal model predictions.
Prenatal THC caused lasting cognitive deficits in both male and female rats through radically different sex-specific mechanisms involving neural activity, proteins, and fatty acid depletion.
Cannabis regulators outlined six research priority areas they say are essential for informed policy, with federal scheduling identified as the main barrier.
Veterans who stopped opioid use were more likely to also stop cannabis and cocaine, and reported improvements in pain and anxiety.
Review found adolescent cannabis use causes lasting cognitive changes through epigenetic modifications and synaptic disruptions, worsened by high-potency products and early initiation.
Among 441 cannabis users, paranoid and dysphoric intoxication experiences were the strongest predictors of motivation to quit, more than psychosis-like hallucinations.
Study of 26,366 births found Black newborns were drug-tested at 3.8x the rate of White newborns without clinical justification, and cannabis legalization did not reduce the disparity.
Comprehensive review found CBD has documented benefits for epilepsy, anxiety, and pain, with emerging evidence for cognition and sleep, but called for better product regulation.
Systematic review of 30 human studies found cannabinoids can cause psychiatric, cognitive, and neurological brain damage, with synthetic cannabinoids posing the greatest risk.
Review found converging evidence that frequent adolescent cannabis use reduces cognition, but debate continues about whether effects persist after quitting and whether brain imaging findings replicate.